Baxter International Inc (BAX) SVP Sells $1,918,947.00 in Stock
Baxter International Inc (NYSE:BAX) SVP Giuseppe Accogli sold 28,641 shares of Baxter International stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Baxter International Inc (NYSE:BAX) opened at $69.18 on Friday. The firm has a market cap of $37,690.00, a PE ratio of 37.39, a PEG ratio of 2.05 and a beta of 0.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.80 and a quick ratio of 2.22. Baxter International Inc has a 12 month low of $44.56 and a 12 month high of $69.35.
Baxter International (NYSE:BAX) last posted its earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.05. The firm had revenue of $2.71 billion during the quarter, compared to the consensus estimate of $2.66 billion. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $0.56 earnings per share. equities research analysts expect that Baxter International Inc will post 2.43 EPS for the current fiscal year.
Several brokerages have commented on BAX. Royal Bank of Canada reaffirmed a “hold” rating and issued a $66.00 price objective on shares of Baxter International in a research report on Wednesday, November 22nd. Morgan Stanley lifted their target price on shares of Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 26th. Zacks Investment Research downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Cowen reiterated a “neutral” rating on shares of Baxter International in a research note on Friday, October 13th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $70.00 target price on shares of Baxter International in a research note on Friday, October 13th. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $68.64.
A number of large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its stake in Baxter International by 0.3% during the third quarter. Bank of New York Mellon Corp now owns 4,978,139 shares of the medical instruments supplier’s stock valued at $312,378,000 after acquiring an additional 16,523 shares in the last quarter. Bessemer Group Inc. grew its stake in Baxter International by 1.4% during the third quarter. Bessemer Group Inc. now owns 4,717,899 shares of the medical instruments supplier’s stock valued at $296,048,000 after acquiring an additional 64,949 shares in the last quarter. New York State Common Retirement Fund grew its stake in Baxter International by 19.0% during the second quarter. New York State Common Retirement Fund now owns 1,830,523 shares of the medical instruments supplier’s stock valued at $110,820,000 after acquiring an additional 291,752 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in Baxter International by 4.6% during the third quarter. Parametric Portfolio Associates LLC now owns 1,666,746 shares of the medical instruments supplier’s stock valued at $104,588,000 after acquiring an additional 73,771 shares in the last quarter. Finally, Teachers Advisors LLC grew its stake in Baxter International by 10.8% during the second quarter. Teachers Advisors LLC now owns 1,542,288 shares of the medical instruments supplier’s stock valued at $93,370,000 after acquiring an additional 149,832 shares in the last quarter. 83.78% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Baxter International Inc (BAX) SVP Sells $1,918,947.00 in Stock” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2018/01/06/baxter-international-inc-bax-svp-sells-1918947-00-in-stock.html.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.